Coiffier Bertrand
Hospices Civils de Lyon, Lyon, France.
Cancer Invest. 2006 Aug-Sep;24(5):548-52. doi: 10.1080/07357900600815232.
Hepatitis B virus (HBV) reactivation is a frequent complication in inactive HBV carriers at time of chemotherapy or following this chemotherapy. This complication appeared during or after chemotherapy and was not increased by the use of rituximab alone or combined with chemotherapy. This is a severe complication most frequently seen in lymphoma patients. Lamivudine have efficacy to treat the patients once the clinical disease is present. However, lamivudine prophylaxis beginning before chemotherapy and until at least 6 months after the end of chemotherapy is recommended for all HBV carriers. Hepatitis C virus is usually not associated with reactivation and prophylaxis should not be used.
乙肝病毒（HBV）再激活是化疗时或化疗后乙肝病毒携带者常见的并发症。这种并发症出现在化疗期间或化疗后，单独使用利妥昔单抗或与化疗联合使用并不会增加其发生率。这是一种严重的并发症，最常见于淋巴瘤患者。一旦出现临床症状，拉米夫定对治疗此类患者有效。然而，建议所有乙肝病毒携带者在化疗前开始使用拉米夫定进行预防，直至化疗结束后至少6个月。丙型肝炎病毒通常与再激活无关，不应进行预防。
